An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Orally Administrated Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Deflazacort (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Marathon Pharmaceuticals; PTC Therapeutics
- 25 Sep 2017 Status changed from active, no longer recruiting to completed.
- 30 Jan 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2017.
- 30 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2017.